Phase III study comparing cisplatin plus gemcitabine with cisplatin ...
WEBJul 20, 2008 · Purpose: Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting.
Efficacy and safety of maintenance pemetrexed in patients with
WEBThe JMDB trial investigated first-line pemetrexed-cisplatin (pemetrexed 500mg/m(2) plus cisplatin 75mg/m(2) every 21 days; maximum: 6 cycles). The PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with nonsquamous NSCLC completed 4 cycles of first-line pemetrexed-cisplatin without disease progression.
Efficacy and safety of pemetrexed maintenance chemotherapy for …
WEBDec 30, 2020 · Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.
Gemcitabine combined with cisplatin as adjuvant chemotherapy …
WEBJul 26, 2017 · Introduction. Lung cancer is the leading cause of cancer‐related death worldwide. 1 Non‐small‐cell lung cancer (NSCLC) represents 80–85% of all lung cancers and surgery remains the best curative treatment option for patients who are diagnosed at an early stage (stage IA–IIIA).
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine ...
WEBBased on the results of JMDB and the recommendation in several clinical guidelines in western countries , Pemetrexed/Cisplatin has also been recommended for the 1st line treatment in Chinese patients with nonsquamous NSCLC in the 2010 Chinese Lung Cancer Clinical Guidelines . According to the requirement from Chinese regulatory authority, this ...
Lung Cancer - ScienceDirect
WEBSep 1, 2014 · Two phase III trials of advanced NSCLC patients were compared to examine relative efficacy and safety of differing treatment regimens. The JMDB trial investigated first-line pemetrexed–cisplatin (pemetrexed 500 mg/m 2 plus cisplatin 75 mg/m 2 every 21 days; maximum: 6 cycles). The PARAMOUNT phase III trial …
WEBThe cross-trial analysis showed that 6 cycles of PC in JMDB compared with 4 cycles in PARAMOUNT increased grade 1/2 fatigue (34.1% vs. 25.0%), anemia (24.0% vs. 13.5%), and renal events (11.8% vs. 3.6%).
Pemetrexed in maintenance treatment of advanced non …
WEBJan 29, 2015 · Pemetrexed, a multitargeting antifolate cytotoxic drug, plays a leading role in front-line chemotherapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). Following its approval as second-line monotherapy for locally advanced or metastatic non-squamous NSCLC, pemetrexed has established itself as …
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin …
WEBJun 29, 2015 · Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial | Journal of Clinical Oncology. Partial Access. ORIGINAL REPORTS. June 29, 2015.
Randomized phase III study of surgery alone or surgery plus ...
WEBJan 10, 2012 · Abstract. Purpose: This study aimed to determine whether three preoperative cycles of gemcitabine plus cisplatin followed by radical surgery provides a reduction in the risk of progression compared with surgery alone in patients with stages IB to IIIA non-small-cell lung cancer (NSCLC).